Aptamer Group extends collaboration with leading biopharmaceutical company to explore next-generation drug delivery approaches
04/03/2021 Aptamer Group, the developer of Optimer™ reagents and therapeutics, today announced the extension of their current agreement with AstraZeneca, a global biopharmaceutical company. This agreement will build upon the existing…